Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR

Carmine Zoccali¹, Francesca Mallamaci²

Affiliations

¹ Renal Research Institute, New York, NY USA; Institute of Molecular Biology and Genetics, Ariano Irpino, Italy; Associazione Ipertensione Nefrologia Trapianto Renal, c/o Nefrologia, Grande Ospedale Metropolitano, 8914 Reggio Calabria, Italy. Electronic address: carmine.zoccali@tin.it.
² Nephrology, Dialysis and Transplantation Unit Azienda Ospedaliera "Bianchi-Melacrino-Morelli" and CNR-IFC, Institute of Clinical Physiology, Research Unit of Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension of Reggio Calabria, Italy.

PMID: 38061373
DOI: 10.1016/S2213-8587(23)00355-8

Comment

Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR

Carmine Zoccali et al. Lancet Diabetes Endocrinol. 2024 Jan.

. 2024 Jan;12(1):5-8.

doi: 10.1016/S2213-8587(23)00355-8. Epub 2023 Dec 4.

Authors

Carmine Zoccali¹, Francesca Mallamaci²

Affiliations

¹ Renal Research Institute, New York, NY USA; Institute of Molecular Biology and Genetics, Ariano Irpino, Italy; Associazione Ipertensione Nefrologia Trapianto Renal, c/o Nefrologia, Grande Ospedale Metropolitano, 8914 Reggio Calabria, Italy. Electronic address: carmine.zoccali@tin.it.
² Nephrology, Dialysis and Transplantation Unit Azienda Ospedaliera "Bianchi-Melacrino-Morelli" and CNR-IFC, Institute of Clinical Physiology, Research Unit of Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension of Reggio Calabria, Italy.

PMID: 38061373
DOI: 10.1016/S2213-8587(23)00355-8

No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment on

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):39-50. doi: 10.1016/S2213-8587(23)00321-2. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061371 Free PMC article. Clinical Trial.
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
EMPA-KIDNEY Collaborative Group. EMPA-KIDNEY Collaborative Group. Lancet Diabetes Endocrinol. 2024 Jan;12(1):51-60. doi: 10.1016/S2213-8587(23)00322-4. Epub 2023 Dec 4. Lancet Diabetes Endocrinol. 2024. PMID: 38061372 Clinical Trial.

References

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR

Affiliations

Empagliflozin in chronic kidney disease: nephroprotection is independent of albuminuria, primary kidney disease, and baseline eGFR

Authors

Affiliations

Conflict of interest statement

Comment on

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Miscellaneous